Axtria, an agentic analytics and cloud software company, along with Mumbai-based private equity firm Kedaara Capital, have completed a $240 million transaction that involves an employee share buyback, providing liquidity to current and former staff as well as early investors.
The deal, which combines secondary investment and a company-sponsored buyback, marks one of the most significant employee-centric liquidity events in the life sciences technology sector.
With this, Kedaara reiterates its commitment to investing in high-quality businesses and highlights the strength of Axtria operating at the intersection of AI, innovation and global life sciences transformation.
Focus on Employees
This transaction provides liquidity to Axtria’s current and former employees, who have played a crucial role in the company’s journey, as well as to its early investors.
Jaswinder Chadha, president and CEO of Axtria, said, “Offering liquidity to our current and former employees is a testament to our ethos. We are proud to build a company that is transforming life sciences through data and agentic AI, while also valuing our people and their contributions.”
Kedaara Capital manages over $5.5 billion in assets and invests across consumer, healthcare, financial services and technology sectors in India.
According to Aashwit Mahajan, director at Kedaara Capital, the partnership would support both organic and inorganic growth opportunities for Axtria. Adding to this, Sunish Sharma, founder and managing partner at Kedaara, said, “We are delighted to support Axtria’s talented workforce as they continue to scale as a trusted partner, helping life sciences companies harness the power of technology and Agentic AI.”
Founded in 2010, Axtria serves over 100 companies across more than 75 countries, including 18 of the world’s top 20 pharmaceutical firms. Its platforms include SalesIQ, CustomerIQ, MarketingIQ and DataMAx.
The company has also recently launched an agentic platform, Axtria InsightsMAx.ai, offering over 30 ready-to-deploy agents, apps and APIs, claiming to help companies transition from experimentation to scaled AI deployment, particularly in the life sciences sector.
